Why ALX Oncology Holdings Inc.’s (ALXO) Stock Is Down 8.13%
As of Wednesday, October 14, ALX Oncology Holdings Inc.’s ALXO share price has dipped by 8.13%, which has investors questioning if this is right time to buy.Jenna Brashear
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
ALX Oncology Holdings Inc., a clinical-stage immuno-oncology company, focuses on developing therapies for cancer patients in the United States. The company’s lead product candidate is Evorpacept, a CD47 blocking therapeutic biologic development as a combination therapy with other anti-cancer agents, including ASPEN-06, under phase 2 clinical study for treating Gastric/GEJ cancer. It has collaboration agreement for Evorpacept combination programs comprising Jazz Pharmaceuticals plc for zanidatamab, under phase 1b/2 trial for the treatment of breast cancer and other solid tumors; HER2 with an ADC, fam-trastuzumab deruxtecan-nxki, under phase 1 trial for the treatment of patients with breast cancer; ALX2004, under phase 1 clinical trial for treating solid tumors; MD Anderson Cancer Center with rituximab and lenalidomide for the treatment of patients with indolent and aggressive NHL; and Sanofi with isatuximab and dexamethasone, under phase 1/2 trial for the treatment of patients with relapsed or refractory multiple myeloma. It has license agreements with Board of Trustees of Leland Stanford Junior University. The company was incorporated in 2015 and is headquartered in South San Francisco, California.
Commentary & Analysis
Why ALX Oncology Holdings Inc.’s (ALXO) Stock Is Down 5.56%
As of Tuesday, October 13, ALX Oncology Holdings Inc.’s ALXO share price has dipped by 5.56%, which has investors questioning if this is right time to buy.Rosalio Madrigal
Why ALX Oncology Holdings Inc.’s (ALXO) Stock Is Down 10.71%
As of Tuesday, October 13, ALX Oncology Holdings Inc.’s ALXO share price has dipped by 10.71%, which has investors questioning if this is right time to buy.Jenna Brashear
Why ALX Oncology Holdings Inc.’s (ALXO) Stock Is Down 5.08%
As of Tuesday, October 06, ALX Oncology Holdings Inc.’s ALXO share price has dipped by 5.08%, which has investors questioning if this is right time to buy.Michael Rose
Why ALX Oncology Holdings Inc.’s (ALXO) Stock Is Down 6.56%
As of Monday, October 05, ALX Oncology Holdings Inc.’s ALXO share price has dipped by 6.56%, which has investors questioning if this is right time to buy.Michael Rose
Financial Summary
| Share Statistics | ALXO | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $123.7 | $218.1 | 24% |
|
| Shares Out (Mil) | 135.6 | 53.9 | 69% |
|
| Institutional Ownership | 98.0% | 93.1% | 76% |
|
| Float (Mil) | 94.7 | 40.9 | 59% |
|
| Beta | 0.40 | 0.95 | 23% |
|
| Avg Daily Volume (000s) | 1,481 | 611 | 77% |
|
| Price Change (52-week) |
(51.6%) | 46.3% | 19% |
|
| Growth | ALXO | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | na | 12.8% | na |
|
| Net Income (5yr) | (17.3%) | (10.2%) | 23% |
|
| EPS (5yr) | 7.2% | 15.7% | 42 |
|
| Dividends (5yr) | na | 0.0% | na |
|
| Cash Flow (5yr) | (14.9%) | (15.7%) | 53% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | na | na | na | |
| Current EPS | ($0.132) | ($0.559) | ($0.545) | |
| Month Ago EPS | na | na | na | |
| # Rev Up | 1 | 0 | 0 | |
| # Rev Down | 0 | 1 | 1 | |
| Three Months Ago EPS | ($0.164) | ($0.649) | ($0.538) | |
| Year/Year Chg | 0.0% | (70.5%) | (72.3%) | |
| Financials | ALXO | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | na | $37 | na |
|
| Net Income (TTM) (Mil) | ($81) | ($44) | 13% |
|
| EPS (TTM) | ($0.933) | ($1.600) | 22% |
|
| Operating Cash Flow (TTM) (Mil) | ($71) | ($33) | 8% |
|
| Net Cash Flow (TTM) (Mil) | $4 | $2 | 50% |
|
| Long-Term Debt (Q1) (Mil) | $10 | $4 | 28% |
|
| Enterprise Value (Q1) (Mil) | $108 | $177 | 22% |
|
| Valuation | ALXO | Industry Median |
Percentile (All Stocks) |
|
| P/B | 0.90 | 2.13 | 21% |
|
| P/E | na | 19.3 | na |
|
| Dividend Yield | na | 0.0% | na |
|
| PEG (5yr hist) | na | 1.1 | na |
|
| Ratios | ALXO | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | na | 66.0% | na |
|
| Net Margin | na | (75.3%) | na |
|
| ROA | (63.2%) | (47.2%) | 9% |
|
| ROE | (80.6%) | (54.2%) | 11% |
|
| Liabilities to Assets | 15.3% | 29.1% | 10% |
|
| F-Score | 3 | 3 | 18% |
|
ALX Oncology Holdings Inc. did not pass any screens on 10/14/2026.
